Status:
COMPLETED
Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe
Lead Sponsor:
Heidelberg University
Conditions:
Type 2 Diabetes
Inflammation
Eligibility:
All Genders
35-80 years
Phase:
NA
Brief Summary
Lowering LDL cholesterol by statins has been proven to be associated with reduction of proinflammatory regulators e.g. activation of the transcription factor NF-ĸB. Up to now the effects of newer chol...
Eligibility Criteria
Inclusion
- 35 to 80 years old
- type 2 diabetes
- HbA1c value between 6.0 % and 9.0 %
- elevated LDL-c values \> 100 mg/dl with no lipid lowering treatment within the last six month
Exclusion
- refused informed consent
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01424891
Start Date
April 1 2004
End Date
August 1 2011
Last Update
August 29 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Heidelberg
Heidelberg, Germany, 69120